Home News Preclinical Data Support Remyelinating Potential of ABX-002 back to News
minute read
ABX-002, an experimental treatment for multiple sclerosis (MS) being developed by Autobahn Therapeutics, promoted the restoration of the myelin sheath in preclinical models of the disease, new data show.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
